Overview

Beta-blockers in Pulmonary Arterial Hypertension

Status:
Terminated

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) < 45% for 6 months.

Phase:

Phase 2

Details

Lead Sponsor:

University of Minnesota
University of Minnesota - Clinical and Translational Science Institute

Treatments:

Adrenergic beta-Antagonists
Carvedilol